Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab) Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2506 STADA will …